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Background. Parkinson’s disease (PD) is the second most common neurodegenerative disorder characterized by numerous motor
and nonmotor symptoms. Neurocognitive disorders (NCD) are one of the most troublesome problems and their diagnosis is often
challenging. Methods. We compared the sensitivity and speciﬁcity of several versions of Addenbrooke Cognitive Examination
(ACE, ACE-III, and Mini-ACE) on 552 subjects with PD. Normal cognition, mild and major NCD were judged in accordance
with the respective criteria of the Diagnostic and Statistical Manual of Mental Disorders 5th edition. Subsequently, we applied
the receiver operation characteristic (ROC) analysis in comparison of diﬀerent education levels. Results. For subjects with
education level 0–8 and 9–12 years, the ACE-III had the best discriminating capabilities for mild NCD (cut-oﬀ scores: 83.5 and
85.5 points, respectively), while Mini-ACE was the best for subjects having education> 12 years (cut-oﬀ score: 25.5 points). For
detecting major NCD, ACE-III had the best diagnostic accuracy in all levels of education (cut-oﬀ scores: 70.5, 77.5, and 78.5
points for subjects having education level 0–8, 9–12, and >12 years, respectively). Conclusion. ACE-III and its nested version,
the Mini-ACE, had the best screening abilities for detecting mild and major NCD in PD.
1. Introduction
Parkinson’s disease (PD) is the second most common neu-
rodegenerative disorder characterized by both motor and
nonmotor symptoms [1]. Besides the well-known motor
symptoms including bradykinesia, resting tremor, and rigid-
ity, numerous nonmotor symptoms (NMS) exist [2]. Among
the NMSs, fatigue, autonomic disturbances, sleep disorders,
depression, apathy, behavioral disturbances, and cognitive
impairments are the most frequent and troublesome [3, 4].
Although some cognitive deﬁcits do exist in the early stages
of the disease interfering executive functions, working mem-
ory, and visuospatial functioning [5, 6], more pronounced
neurocognitive disorders (NCDs) may develop as the disease
progresses [7, 8]. These neuropsychological deﬁcits are partly
related to the dysfunction of dopaminergic frontostriatal
circuits [9, 10].
NCDs are characterized by a decline from a previously
attained level of cognitive functioning. This decline should be
both clinically relevant in manner and objectively measurable
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in order to establish the diagnosis. In the clinical practice,
basically, two diagnostic frameworks exist for diagnosing
NCDs in PD.
The Task Forces and Committees of the International
Parkinson’s Disease and Movement Disorders Society
(IPDMDS) established the criteria for mild cognitive impair-
ment in PD (PD-MCI) [11] and the Parkinson’s disease
dementia (PDD) [12]. Although PD-MCI might develop in
the early stages of PD [13], it is more characteristic of later
phases. PD-MCI is deﬁned as a stage between dementia and
normal cognitive functioning with subjective concern and
objective decline of cognitive functioning, without major
impairment in the everyday functions [11, 14]. In addition
to executive dysfunction, there is an alteration of posterior
cortical functions in PD-MCI [15]. Prevalence of PD-MCI
is increased by age, disease duration, and disease severity
[11, 14]. Diagnosing PD-MCI is an important issue because
PD-MCI predicts the development of dementia [16]. The
establishment of the diagnosis of the PD-MCI is based on
abbreviated (Level-I) and comprehensive (Level-II) assess-
ments [11]. In accordance with the IPDMDS Task Force
Guidelines, in PD-MCI, the cognitive functions (memory,
executive function) are 1 to 2 standard deviations below the
average level. PDD has more severe cortical dysfunctions
compared with PD-MCI [12, 15]. Cortical proﬁle of PDD
represents an impairment of memory and language skill,
while subcortical proﬁle has a decline in attention, executive
and visuospatial functions [17, 18]. PDD usually develops
several years after the onset of motor symptoms [12]. The
prevalence of PDD is approximately 20–40% [19–21]. The
IPDMDS Task Force Guidelines provides a guideline for a
diagnostic procedure for determining PDD [19, 22]. The
diagnostic procedure also consists of abbreviated (Level-I)
and comprehensive (Level-II) assessment as it is shown in
PD-MCI. Detecting PDD is extremely important in the treat-
ment of PD and in screening appropriate candidates for deep
brain stimulation.
The ﬁfth edition of the Diagnostic and Statistical Manual
of Mental Disorders (DSM-5) also provides a common
framework for the diagnosis of neurocognitive disorders, ﬁrst
by describing the main cognitive syndromes and then deﬁn-
ing criteria to delineate speciﬁc etiological subtypes. The
DSM-5 deﬁnes the mild and major NCDs in PD, which
largely overlap with the PD-MCI and PDD terminology.
Diagnosing dementia in Parkinson’s disease patient pop-
ulation poses signiﬁcant challenges. The screening procedure
includes several tests for the abbreviated assessment of PDD.
These screening tools may represent short (Mini-Mental
State Examination (MMSE) and Montreal Cognitive Exami-
nation [23] (MoCA)) and “longer” test batteries (e.g., Mattis
Dementia Rating Scale and the Addenbrooke’s Cognitive
Examination) [19, 22, 24, 25].
The Addenbrooke’s Cognitive Examination (ACE), a
screening tool, has had substantial and rapid development
over the years. The original version of ACE (ACE-I) was
developed to diﬀerentiate Alzheimer’s disease from fronto-
temporal dementia and to detect the early stages of these
dementia syndromes [26]. The maximum score of ACE-I is
100, and higher numbers represent better functioning.
ACE-I assesses six cognitive domains, where the maximum
scores are 10 points for orientation, 8 points for attention,
35 points for memory, 14 points for verbal ﬂuency, 28 points
for language skills, and 5 points for visuospatial ability. ACE-
I also includes the nested version of MMSE. The Spanish ver-
sion of ACE-I was able to detect dementia in PD, and it could
discriminate PDD from Alzheimer’s dementia but not from
frontotemporal dementia [27].
The Addenbrooke’s Cognitive Examination-Revised
(ACE-R) was developed soon after the publication of ACE-
I considering the strengths and weaknesses of ACE-I [28]
and had been translated into many languages [29–33]. While
ACE-I has only one version, the ACE-R includes three alter-
native versions, allowing multiple testing over extended
time. Signiﬁcant changes were made in the language and
visuospatial parts. ACE-R has ﬁve subscores representing
various cognitive domains: attention/orientation (18 points),
memory (26 points), verbal ﬂuency (14 points), language
skills (26 points), and visuospatial abilities (16 points). The
maximum score is 100 in ACE-R. Recently, ACE-R has been
used extensively worldwide [29, 32–34].
The newest version of the ACE test family is the
Addenbrooke’s Cognitive Examination-III (ACE-III) [35].
Its maximum score is also 100 points. Compared to ACE-R,
ACE-III has some modiﬁcations in the attention domain,
the syntactical and semantical complexity of language skill,
and visuospatial ability items to accommodate removal of
MMSE items. ACE-III assesses the domain of attention (18
points), memory (26 points), verbal ﬂuency (14 points), lan-
guage (26 points), and visuospatial (16 points) functions.
ACE-III cognitive subscores correlate with the scores of com-
prehensive neuropsychological tests, and ACE-III has similar
sensitivity and speciﬁcity for detecting Alzheimer’s disease
and frontotemporal dementia as ACE-R.
One of the most important diﬀerences is that the ACE-III
does not provide the score of MMSE anymore. Therefore, a
short form, the Mini-Addenbrooke’s Cognitive Examination
(Mini-ACE), was derived from ACE-III [36]. The adminis-
tration time of ACE-III is 15–20minutes, whereas Mini-
ACE takes about 5 minutes to complete. Mini-ACE consists
of only ﬁve items (attention: 4 points; memory: 7 points; ver-
bal ﬂuency: 7 points; clock drawing: 5 points; recall: 7 points)
with a maximum score of 30. The Mini-ACE can be assessed
as a stand-alone screening instrument or as a nested version
in the ACE-III. Although several language validations of
ACE-III and Mini-ACE exist [37–40], the diagnostic accu-
racy of ACE-III or Mini-ACE in the diagnosis of PD-MCI
and PDD has not been investigated.
In the present study, we aimed to compare the sensi-
tivity and speciﬁcity of the diﬀerent ACE variants available
in Hungarian (ACE-I, ACE-III, and Mini-ACE) for detect-
ing mild and major NCD in PD in accordance with the
DSM-5 criteria.
2. Materials and Methods
Five hundred and seventy-nine consecutive PD patients were
recruited for the study. Patients were treated at the Depart-
ment of Neurology, University of Pécs. Each patient fulﬁlled
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the clinical diagnostic criteria for PD [41] and gave written
informed consent according to the approval of the Regional
Ethical Board of the University of Pécs.
History of alcoholism, cerebrovascular disease, and other
conditions known to impair mental status served as exclusion
criteria for participation. Each patient had a routine brain
MRI (or brain CT if the MRI examination was contraindi-
cated). Patients with focal abnormalities on neuroimaging
studies, abnormalities in thyroid hormone levels, or uncom-
pensated systemic diseases (i.e., diabetes, hypertension, and
heart failure) were also excluded. According to the above-
mentioned criteria, twenty-seven patients were excluded
from the study.
Patients were evaluated using the Hungarian version of
Mini-Mental State Examination (MMSE) [42], Addenbrooke
Cognitive Examination I (ACE-I) [22] and III (ACE-III),
Mini-Addenbrooke Cognitive Examination (Mini-ACE),
Montgomery-Asberg Depression Rating Scale (MADRS)
[43], and the Lille Apathy Rating Scale (LARS) [44, 45].
The severity of Parkinsonian symptoms was evaluated by
the Hoehn-Yahr stage (HYS) [46], the Movement Disorders
Society-sponsored Uniﬁed Parkinson’s Disease Rating Scale
(MDS-UPDRS) [47], and the Uniﬁed Dyskinesia Rating
Scale (UDysRS) [48] if motor complications were present.
Subsequently, PD patients were divided into three groups
based on the DSM-5 criteria: patients with major neurocog-
nitive disorder (major NCD group), mild neurocognitive dis-
order (mild NCD group), and patients without any NCD
(normal cognition) [24, 25].
Statistical analysis was performed using IBM SPSS (ver-
sion 19, a SPSS Inc. IBM) and R for Windows 3.1.2 statistical
software. Because data did not follow a normal distribution,
Kruskal-Wallis nonparametric test was applied. Since HY
and sex are dichotomous and categorical variables, Pearson’s
chi-square and Kendall-tau tests were applied to these vari-
ables. Receiver operating characteristic curve statistics for
MMSE, ACE-I, ACE-III, and Mini-ACE were calculated in
SPSS software.
3. Results
A total of 27 patients were excluded for the further analyses
because of the presence of clinically severe depression and/
or anxiety judged by the neuropsychological examination
or abnormalities present on the neuroimaging. Out of 552
evaluated PD patients, 277 had normal cognition, 165 had
mild NCD, and 110 had major NCD according to DSM-5
classiﬁcation. Table 1 shows the demographic and clinical
characteristics of these groups. Except for levodopa equiva-
lent dose (LED, mg) and sex, all demographic and clinical
variables showed signiﬁcant diﬀerences. There were signiﬁ-
cant diﬀerences in the total scores and the subscores of
ACE-I, ACE-III, Mini-ACE, and MMSE between normal,
mild, and major NCD groups.
Table 2 shows the results of the ROC analysis of detecting
mild NCD based on the diﬀerent levels of education years.
According to Youden’s index, ACE-III has the best diagnos-
tic accuracy in individuals having 0–8 years of education
(sensitivity: 93%; speciﬁcity: 64%, area under curve (AUC)
area: 73%, cut-oﬀ score: 83.5 points) and 9–12 years of edu-
cation (sensitivity: 80%, speciﬁcity: 78%, AUC area: 77%,
cut-oﬀ score: 85.5 points). However, the Mini-ACE test
has the best performance among subjects with >12 years
of education (sensitivity: 71%, speciﬁcity: 79%, AUC area:
82%, cut-oﬀ score: 25.5 points).
For detecting major NCD (Table 3), ACE-III test has a
best diagnostic accuracy across all levels of education.
Among subjects with 0–8 years of education, its sensitivity
and speciﬁcity was 80% and 90%, respectively (AUC: 89%,
the cut-oﬀ score was 70.5 points). In PD patients with 9–12
years of formal education, the speciﬁcity and sensitivity of
ACE-III was 90% and 74%, respectively (AUC area: 92%
and the cut-oﬀ score: 77.5 points). In individuals having
more than 12 years of education, its sensitivity and sensitivity
was 95% and 92%, respectively (AUC: 97%, and the cut-oﬀ
score: 78.5 points).
4. Discussion
Cognitive impairment inﬂuences the quality of life of Parkin-
son’s patients and is detectable in newly diagnosed patients
[6, 45, 49]. The diagnosis of PD-MCI is important because
it could inﬂuence the therapeutic decisions and it also could
be the harbinger of PDD [13, 50]. The frequency of PD-
MCI and dementia in PD may be about 30% depending on
the age, disease duration, and comorbidities. Based on its
clinical relevance, it is critical to identify mild and major neu-
rocognitive disorders in PD. Therefore, reliable, valid, and
accurate screening tests are warranted in the clinical practice.
The three diﬀerent variants of the Addenbrooke’s Cogni-
tive Examination may help establish the Level-I diagnosis
[19]. The ACE test was originally developed for the discrim-
ination of Alzheimer’s disease from frontotemporal dementia
[26]. Reyes et al. demonstrated 92% sensitivity and 91% spec-
iﬁcity of ACE-I (cut-oﬀ score: 83) in the detection of demen-
tia of a small number of patients with Parkinson’s disease
[51]. In a small group of Hungarian subjects with Parkinson’s
disease, the ACE-I sensitivity and speciﬁcity in detecting
dementia were 74% and 78.1% with 80 point cut-oﬀ score
of [22]. Lucza et al. demonstrated 83.5 point cut-oﬀ score
of ACE-I (sensitivity: 87.1%, speciﬁcity: 79.7%) in diﬀeren-
tiating mild neurocognitive disorder in PD, and 80.5
points (sensitivity: 86.9%, speciﬁcity: 73.7%) in PD with
major neurocognitive disorder [24, 25].
The next version of the Addenbrooke’s test family, the
ACE-R, has never been formally translated and validated in
Hungary. Therefore, in this study, we could not evaluate its
discriminative capabilities. However, it has been utilized
internationally for screening PD-MCI and PDD. The sensi-
tivity and speciﬁcity of ACE-R detecting PD-MCI are 69%
and 84% with 89 point cut-oﬀ score of [52]. ACE-R was also
used to diﬀerentiate cognitive functions in PD from Parkin-
sonian syndromes [53]. This study demonstrated the useful-
ness of verbal ﬂuency subscore in the diﬀerential diagnosis of
PDD from Parkinsonism. ACE-R has 85.5 point cut-oﬀ score
(sensitivity: 68%, speciﬁcity: 91%) in discriminating PD-MCI
from PD with normal cognition and 82.5 points (sensitivity:
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70%, speciﬁcity: 73%) in discriminating PD-MCI from PDD
in Czech PD population (a sample of 69 persons) [54].
The newest versions of the ACE test batteries, the ACE-
III and Mini-ACE, have never been tested previously for
the detection of mild and major NCD in PD (PubMed search
using the keywords “Parkinson’s disease” AND “ACE-III”
OR “Parkinson’s disease”AND “ACE III”, performed on July
29, 2018). In our cohort of patients, ACE-III had better dis-
criminative abilities than ACE-I had. Moreover, ACE-III
was also better in screening for mild and major NCD than
the MMSE. Generally, the discriminative accuracy of Mini-
ACE was between those of ACE and ACE-III with the excep-
tion of screening for mild NCD in PD among subjects
having> 12 years of formal education.
As far as the authors are aware of, this is the ﬁrst valida-
tion study of ACE-III and Mini-ACE for detecting mild and
major NCDs in PD. In the present study, we demonstrated
that ACE has an acceptable sensitivity for detecting bothmild
andmajor NCD; however, its speciﬁcity was below the expec-
tation in the group of patients having low education levels
(up to and including 8 years of education). One of the
strengths of our study was that we could establish valid and
reliable discriminative thresholds for diﬀerent education
levels. Although we have included a large pool of patients
with wide age distribution and various disease severity stages
to improve the consistency of our data, we are also aware of
some limitations. Despite of measuring the MADRS, we did
not use these scores for excluding patients with depression.
Table 2: Diagnostic accuracy of ACE-I, ACE-III, Mini-ACE, and MMSE for detecting mild neurocognitive disorder in the respect of
education years.
Mild
neurocognitive
disorder
Best cut-oﬀ
score
Sensitivity Speciﬁcity Youden’s index Positive likelihood ratio Negative likelihood ratio AUC area
ACE-I
0–8 84.5 0.862 0.571 0.433 2.011 0.241 0.713
9–12 86.5 0.850 0.614 0.464 2.204 0.244 0.787
>12 90.5 0.847 0.626 0.473 2.263 0.244 0.819
ACE-III
0–8 83.5 0.931 0.643 0.574 2.607 0.107 0.733
9–12 85.5 0.805 0.786 0.511 2.917 0.477 0.771
>12 88.5 0.765 0.744 0.509 2.985 0.316 0.838
Mini-ACE
0–8 23.5 0.793 0.714 0.507 2.776 0.290 0.749
9–12 24.5 0.850 0.514 0.364 1.750 0.292 0.746
>12 25.5 0.718 0.798 0.516 3.553 0.354 0.820
MMSE
0–8 26.5 0.414 0.857 0.271 2.897 0.684 0.602
9–12 27.5 0.575 0.743 0.318 2.236 0.572 0.723
>12 28.5 0.612 0.714 0.326 2.141 0.544 0.696
Table 3: Diagnostic accuracy of ACE-I, ACE-III, Mini-ACE, and MMSE for detecting major neurocognitive disorder in the respect of
education years.
Major
neurocognitive
disorder
Best cut-oﬀ
score
Sensitivity Speciﬁcity Youden’s index Positive likelihood ratio Negative likelihood ratio AUC area
ACE-I
0–8 74.5 0.821 0.744 0.565 3.207 0.241 0.871
9–12 76.5 0.848 0.773 0.622 3.743 0.196 0.915
>12 80.5 0.903 0.927 0.881 13.076 0.050 0.974
ACE-III
0–8 70.5 0.805 0.907 0.702 8.545 0.226 0.895
9–12 77.5 0.909 0.740 0.649 3.497 0.123 0.926
>12 78.5 0.957 0.927 0.894 12.439 0.100 0.972
Mini-ACE
0–8 17.5 0.718 0.791 0.509 3.430 0.357 0.833
9–12 20.5 0.833 0.747 0.580 3.289 0.223 0.894
>12 21.5 0.907 0.917 0.824 10.884 0.101 0.968
MMSE
0–8 25.5 0.744 0.860 0.604 5.329 0.298 0.866
9–12 26.5 0.803 0.780 0.583 3.650 0.253 0.868
>12 27.5 0.814 0.809 0.623 4.262 0.230 0.903
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Because the symptoms of depression are largely overlapping
with numerous features of PD (e.g., slowness of thinking, sex-
ual disturbances, and changes in appetite) and many subjects
experience nonmotor ﬂuctuations (e.g., having depressed
mood or anxiety in OFF state while not having such phenom-
ena in the ON periods), they might have higher MADRS
scores without clinically signiﬁcant depression. Therefore,
we decided to exclude only those patients who had severe
depression diagnosed by the neuropsychologists (n = 27)
but not based on the MADRS values alone.
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